This mechanism of action may offer a restorative therapeutic index and provide a scientific rationale to treat selected patients with TET2 mutant–associated or TET deficiency–associated myeloid malignancies. The gene discussed is TET2; the disease is hyperinsulinemic hypoglycemia, familial, 4.